

Summary of Arguments and Remarks

Amendments to Claims

- The amendment to claim 16 emphasizes the nature and features of the isolated antibody as binding to living MCF-7 or 3T3 cells expressing human or murine BCRP on their surface, and that antibodies of the present invention do not bind to MCF-7 cells that do not express human or murine BCRP on their surface. Support for this claim may be found in paragraphs 74-77 of the published specification.
- New claims 29 and 30 are directed to antibodies operably attached to a detectable label and immunodetection kits. Support for these claims may be found in paragraphs 73-81 of the published specification.
- New claim 31 is directed to an isolated antibody isolated according to the steps involving immunizing a mouse with 3T3 cells that express human or murine BCRP in its natural conformation on the cell surface and selecting and isolating a desired hybridoma. New claim 32 claims an antibody isolated from a hybridoma generated by the steps recited in claim 31. Support for these claims may be found in paragraphs 74-77 of the published specification. Claims 31 and 32 should be examined together with the presently pending claims, since they encompass an antibody product with the same binding properties as that of claim 16. Examining claims 31 and 32 in the present case would not present any additional searching burden for the Examiner.
- As amended, the claims are fully supported by the written description, are enabled, and are distinct from the prior art.